Clinical Trials Logo

Clinical Trial Summary

The perioperative management of esophageal cancer has evolved considerably in recent years. Over the last 30 years, postoperative mortality has been steadily decreasing. However, respiratory morbidity remains high (30-40%). This is due to the procedure itself requiring a thoracic approach and intraoperative unipulmonary ventilation. The postoperative pulmonary complications (PPCs) are multiple: bronchial congestion, atelectasis, pneumopathy, acute respiratory distress syndrome (ARDS), liquid pleural effusion, pneumothorax. In general, prevention and early treatment are aimed at limiting the evolution towards acute respiratory failure requiring ventilatory assistance. Chest radiography is essential for the presumptive diagnosis of pneumopathy in particular, but the interpretation of the images may be difficult. Thoracic computed tomography (CT) is the gold standard because it is sensitive and can discriminate among differential diagnoses. This is difficult to perform: it requires intra-hospital transport of patient, who is often in acute respiratory failure, and the availability of an examination area. Lung ultrasound is used at the bedside for diagnosis of lung infection in intensive care unit. This has a sensitivity close to thoracic CT and has the advantage of being feasible at any time, does not require transport of the patient and is not irradiating. Lung ultrasound allows early detection of the need for ventilatory support in postoperative major abdominal surgery . In addition, the sensitivity of lung ultrasound is close to that of CT, allowing this examination to be relied upon. The main objective of the study is to determine the role of lung ultrasound in the prediction of postoperative pulmonary complications within one hour after extubation.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05453760
Study type Observational
Source University Hospital, Lille
Contact Cédric CIRENEI, MD,PhD
Phone 0320445962
Email cedric.cirenei@chu-lille.fr
Status Recruiting
Phase
Start date August 21, 2022
Completion date January 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05176002 - Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma. Phase 1/Phase 2
Not yet recruiting NCT05406024 - Feasibility Study CORPPS
Terminated NCT02601079 - Endodrill vs. Conventional Biopsy. Diagnostics and Genetic Analysis N/A
Active, not recruiting NCT01745107 - Efficacy of Intensity Modulated Radiation Therapy After Surgery in Early Stage of Esophageal Carcinoma; Phase 3
Active, not recruiting NCT02969473 - Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma Phase 2
Recruiting NCT04481100 - CCRT With Itraconazole in Locally Advanced Squamous Esophageal Cancer Phase 2
Terminated NCT03108885 - Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker of Response and Recurrence
Recruiting NCT00288119 - Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Terminated NCT01870791 - Study of Additive Omega-3 Fish Oil to Palliative Chemotherapy to Treat Oesophagogastric Cancer Phase 2
Active, not recruiting NCT00431756 - Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus
Not yet recruiting NCT05736705 - Monopolar and Bipolar in Esophageal ESD N/A
Completed NCT02395705 - Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma Phase 3
Completed NCT02033213 - Volume Restriction in Esophageal Carcinoma Surgery: Randomized Clinical Trial N/A
Terminated NCT00653107 - Palliation Dysphagia Cancer Oesophagus Stent+Brachytherapy Versus Brachytherapy Only Phase 3
Completed NCT01927016 - Outcomes After Esophageal Cancer Surgery N/A
Completed NCT02558504 - Radiofrequency in the Treatment of Barrett's Oesophagus Phase 4
Active, not recruiting NCT02636088 - Definitive Chemoradiotherapy and Cetuximab in the Treatment of Locally Advanced Esophageal Cancer Phase 2
Terminated NCT00423150 - Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED) Phase 2
Completed NCT00318903 - Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer Phase 2
Recruiting NCT02583087 - ESD for the Treatment of Early Barrett's Neoplasia N/A